Topchoice - A Hidden uncertainties behind the fragile smile of China's dental giant: Initiate with UW We initiate coverage of Topchoice with an UW rating and a Dec-25 PT of Rmb34. Topchoice is one of the top dental chains in China, operating 84 medical facilities and equipped with ~3,100 dental chairs as of 3QFY24. We see dental services facing short- and long-term challenges, leading to profitability pressure. Our FY25E/26E EPS is 8%/10% below consensus. The prospect of weaker-than-expected earnings growth ...

Investment Rating - The report maintains a "Buy" rating for Zhongji InnoLight with a target price reduced to CNY 125, implying a 54% upside from the closing price of CNY 81.19 on April 21, 2025 [5][26]. Core Insights - The company experienced significant revenue and earnings growth in FY24, with year-on-year revenue growth of 122.6% and earnings growth of 142.6%. However, 1Q25 revenue growth was subdued at 37.8% year-on-year due to a shortage of EML chips, while earnings rose 56.8% year-on-year, driven by better gross profit margins [1][2][19]. - Demand for 800G transceivers is expected to remain strong, while demand for 1.6T transceivers may slow down this year but is anticipated to ramp up next year. The easing of the EML chip shortage is expected to improve shipment volumes in the coming quarters [2][19]. - The report highlights that a temporary tariff exemption is currently easing margin pressure and may boost near-term shipments, although the risk of a tariff hike remains a concern [3][19]. Financial Summary - FY24 revenue was reported at CNY 23,862 million, with a projected revenue of CNY 37,228 million for FY25 and CNY 41,462 million for FY26. The normalized net profit for FY24 was CNY 5,171 million, with projections of CNY 8,202 million for FY25 and CNY 9,373 million for FY26 [4][10]. - The gross profit margin (GPM) is expected to improve slightly, with FY25-26F GPM raised by 0.1 percentage points due to a better product mix [16][19]. - The company is currently trading at a normalized P/E of 9.7x for FY26F, which is below the median P/E range of the China electronic/communication component companies [1][4][19].

Investment Rating - The investment rating for Wanhua Chemical is Underweight [2][8][76] Core Views - The report indicates that Wanhua Chemical is facing multiple geopolitical headwinds, including US export tariffs on MDI, China's import tariffs on ethane, and an anti-dumping investigation by the US, which are expected to negatively impact volume, price, and earnings [8][12][13] - The price target for Wanhua Chemical has been reduced to Rmb51.00, reflecting a 5% decrease based on updated financial data and a target multiple of 15x 2025e P/E [5][8][12] Summary by Sections Price Target and Earnings Estimates - The price target for Wanhua Chemical is set at Rmb51.00, down from Rmb54.00, based on a target multiple of 15x 2025e P/E [5][8] - The estimated EPS for 2025 is revised to Rmb3.42, down from Rmb3.61 [2][8] Financial Performance and Projections - The report projects a decline in net profit by 5% for 2025 and 6% for 2026, leading to a downward revision of earnings estimates [5][8] - MDI prices are expected to be Rmb12,305 per ton in 2025, with unit gross profit projected at Rmb2,892 per ton [16] Market Conditions and Risks - The geopolitical risks are anticipated to exert downward pressure on MDI prices and spreads, affecting overall earnings visibility for non-MDI products [8][12][13] - The report highlights that the valuation is no longer appealing, contributing to the Underweight rating [8][12]

We are also watchful about Hainan's free-trade-zone policy and impact to duty-free operators. The Hainan government has not yet released any details, but we expect it to do so later this year as Central government targets opening the FTZ in 2025. Recap of March-2025 Hainan offline DF trends: Avg daily sales Rmb94mn (-5% YoY vs -13% YoY in 2M25); Daily shoppers 17.7K (-26% YoY) and spending per shopper Rmb6.5K (+28%). The ASP growth could be helped by more electronic product sales which might not translate t ...

Investment Rating - The investment rating for Hangzhou Hikvision Digital Technology is Neutral, with a target price adjusted to Rmb30 from Rmb33, reflecting a 5.7% expected return [4][21][22]. Core Insights - The company reported 4Q24 results that were in line with preliminary results, with a revenue decrease of 2% YoY to Rmb27.5 billion and a net profit decline of 26% YoY to Rmb3.9 billion [2][10]. - For 1Q25, revenue increased by 4% YoY to Rmb18.5 billion, although it was below expectations [1][11]. - Management plans to focus on higher-margin businesses and maintain strict control over operating expenses [8][21]. - There is an expectation of muted recovery in domestic business for FY25, while overseas and innovative business segments are anticipated to grow stronger [8][21]. Summary by Sections Financial Performance - 4Q24 revenue was Rmb27.5 billion, down 2% YoY, with a gross margin of 41%, down 1.9 percentage points YoY [2][10]. - 1Q25 revenue rose to Rmb18.5 billion, with a gross margin of 43.9%, down 0.8 percentage points [1][11]. - FY24 revenue for the PBG segment decreased by 12% YoY, while the innovation business grew by 21.2% YoY to Rmb22.5 billion [2][10]. Earnings Estimates - FY25-26 earnings estimates have been cut by 11-16% due to lower revenue and margin assumptions [9][13]. - The new revenue estimate for FY25 is Rmb98.986 billion, down 3.2% from the previous estimate [13][14]. Market Position and Strategy - Hikvision is the world's largest supplier of video surveillance products, focusing on innovation and expanding its overseas business [20][21]. - The company has ceased shipments to the US, which previously accounted for about 3-4% of sales, with limited expected impact on overall business [8][21]. Valuation Metrics - The target price of Rmb30 is based on a 20.2x NTM PE, which aligns with the company's 10-year historical average [4][22]. - Current market capitalization is Rmb261.946 billion [4].

中国 证券研究 2025 年 4 月 21 日 通策医疗 - A 中国口腔医疗巨头脆弱微笑背后潜藏的不确定性：首 次覆盖，给予"减持"评级 我们首次覆盖通策医疗，给予"减持"评级和截至 2025 年 12 月的目标价 34 元。通策医疗是中国领先的口腔医疗连锁机构之一，截至 2024 年 3 季 度，公司经营有 84 家医疗机构，开设牙椅约 3100 台。我们认为口腔医 疗服务行业面临短期及长期挑战，导致盈利承压。我们的 2025/26 年每 股收益预测值分别比市场一致预期低 8%/10%。盈利增长前景弱于预期 以及对浙江省的地域依赖（收入九成来自省内）使我们很难合理化当前 估值倍数，我们认为该股股价此后将趋缓。 资料来源：风格敞口数据源自摩根大通量化与衍生品策略团队；其他所有图表中的数据均为公司数据或摩根大通估算 分析师声明及重要披露，包括非美国分析师披露，见第 30 页。 摩根大通与其研究报告所覆盖的公司开展业务，或寻求与这些公司开展业务。因此，投资者应意识到其中可能存 在利益冲突，进而可能会影响本报告的客观性。投资者在做出投资决策时，本报告之观点应仅作为投资者的考虑 因素之一。 首次覆盖 减持 6007 ...

Investment Rating - The investment rating for China TransInfo Technology is "Sell" with a target price of Rmb5.1, indicating an expected share price return of -38.0% and a total expected return of -37.6% [4][8]. Core Insights - In 4Q24, revenue decreased by 28% year-over-year to Rmb1.8 billion, which was 40% and 25% below CitiE and BBGe estimates respectively [2][6]. - The gross margin for 4Q24 fell by 5.4 percentage points year-over-year to 32.1%, which was 6.1 percentage points below CitiE but 4.5 percentage points above BBGe [2][6]. - Operating expenses increased by 3% year-over-year to Rmb796 million, leading to an operating loss of Rmb206 million compared to an operating profit of Rmb179 million in 4Q23 [2][6]. - The overall net loss for 4Q24 was Rmb1.2 billion, aligning with previous guidance [2][6]. - For FY24, revenue declined by 7% year-over-year, with net losses also at Rmb1.2 billion compared to a net profit of Rmb542 million in FY23 [2][6]. Segment Breakdown - In the second half of 2024, revenue from intelligent transportation fell by 54% year-over-year to Rmb798 million, while the overall FY24 revenue for this segment decreased by 26% year-over-year to Rmb2.2 billion [3]. - The gross margin for the intelligent transportation segment narrowed by 12 percentage points year-over-year to 19.5% in 2H24, and the FY24 gross margin decreased by 7.3 percentage points to 21.1% [3]. - Conversely, revenue from intelligent IoT increased by 7% year-over-year to Rmb2.9 billion in 2H24, with an overall FY24 revenue growth of 5% year-over-year to Rmb5.1 billion [3].

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The average tariff imposed by the US has surged from 3% to over 20%, marking the highest level in nearly a century, which has led to significant declines in stock and commodity prices, reminiscent of the Smoot-Hawley Tariff Act of the 1930s [1][2] - High tariffs disrupt global supply chains, forcing companies to adjust production layouts, which reduces global production efficiency and raises the US policy uncertainty index to its second-highest level in decades [1][5] - The imposition of tariffs is expected to push inflation higher, slow down economic growth in exporting countries, and suppress overall production, leading to a lasting negative impact on the macroeconomy [1][6] - The report predicts a potential recession or stagflation in the US economy, with GDP expected to drop sharply and both consumption and investment slowing down, contrasting with the prevailing belief in the resilience of the US economy [1][8] - Economic data in the US shows significant divergence, with soft data (like consumer confidence) not aligning with hard data (like sales figures), necessitating careful differentiation between core and auxiliary data to avoid reliance on distorted information [1][12] Summary by Sections Tariff Impact - The US government has announced a significant increase in tariffs, raising basic tariffs by 10% and imposing tariffs of 30% to 50% on countries with large trade deficits with the US, resulting in an average tariff increase to over 20% [2][3] - This tariff increase has led to a notable decline in US stock markets and commodity prices, indicating a substantial negative impact on the economy [4][5] Economic Outlook - The report suggests that the US economy may face a challenging future, with a high likelihood of recession or stagflation due to the adverse effects of tariffs and other policies [7][8] - The analysis indicates that the most resilient sectors, such as consumption and investment, are also showing signs of slowing down, confirming the overall downward trend in the economy [17][18] Global Economic Context - China's economy showed a GDP growth of 5.4% in the first quarter, but is expected to face challenges in the second and third quarters due to tariff impacts, with potential government measures to stabilize recovery [19][20] - The report emphasizes the importance of considering the contrasting policy environments between the US and China, with China having more room for counter-cyclical stimulus due to lower inflation [20][21] Asset Allocation Recommendations - In the current environment, the report recommends allocating to safe assets like gold and Chinese bonds, while advising caution regarding traditional safe assets like US dollars and bonds due to their diminished safety and resilience [44][38] - The report suggests that investors should maintain a cautious stance towards US equities, given the potential for recession or stagflation, and consider structural adjustments in their portfolios [39][42]

Investment Ratings - Dahua: Sell [1][2][39] - Arcsoft: Sell [1][14][36] - Chinasoft Intl.: Neutral [1][24][34] Core Insights - Dahua launched the Xinghan foundation model 2.0 to enhance product competitiveness, but market demand is expected to remain low in 2025, particularly in China [2][3] - Arcsoft's growth is driven by AI and smart driving technologies, with management targeting high double-digit to triple-digit revenue growth in 2025 [14][15] - Chinasoft Intl. is expected to recover in 2025, driven by Huawei's product deployment and a positive outlook for traditional IT services [24][25] Dahua Summary - 1Q25 net income increased by 16% YoY to RMB 653 million, but was 14% below estimates; revenues were up 1% YoY but down 36% QoQ [3][7] - Earnings estimates for 2025-2027 were revised down by 21%, 16%, and 15% respectively due to lower revenue visibility and increased R&D investments [8][10] - Target price revised down to RMB 14.28, reflecting a 9% downside [10] Arcsoft Summary - 1Q25 revenues were up 14% YoY to RMB 209 million, but 10% lower than estimates; net income was up 45% YoY to RMB 50 million [15][16] - Earnings estimates for 2025-2026 were revised down by 19% and 15% respectively, reflecting competition and modest demand [21][22] - Target price revised up to RMB 37.5, indicating a 14% downside [22] Chinasoft Intl. Summary - 2H24 revenues returned to positive YoY growth at +4%, with operating income largely in line with estimates [27][29] - Earnings estimates for 2025-2027 were cut by 3%, 2%, and 2% respectively due to gross margin misses and pricing pressures [30][34] - Target price set at HK$5.5, based on a 15.4x 2025E P/E [34]

Investment Rating - The report maintains a "Buy" rating for Eoptolink, with a revised 12-month target price of Rmb123, indicating a potential upside of 51.5% from the current price of Rmb81.2 [9][17]. Core Insights - Eoptolink's revenue for 1Q25 reached Rmb4.05 billion, representing a 264% year-over-year increase and a 15% quarter-over-quarter increase, which aligns closely with Goldman Sachs' estimate of Rmb3.99 billion. The net profit of Rmb1.57 billion exceeded estimates by 11%, driven by strong margin expansion with a gross margin of 48.7% [1][2]. - The company is well-positioned to benefit from the ramp-up of 400G and 800G optical transceivers, particularly in AI infrastructure, which is expected to be a primary earnings driver in 2025 [15]. - Eoptolink's net profit has converged with that of its larger peer, Innolight, despite having a market capitalization that is only 65% of Innolight's, suggesting a potential narrowing of the valuation gap due to Eoptolink's strong profitability and growth momentum [1][12]. Summary by Sections Revenue and Profitability - Eoptolink's revenue growth has been robust, with sequential increases of 49%, 46%, and 15% quarter-over-quarter in 3Q24, 4Q24, and 1Q25, respectively. The company is expected to achieve a net profit of Rmb6.4 billion in 2025, reflecting a year-over-year growth of 126% [2][9]. - The gross margin has shown significant improvement, reaching 48.7% in 1Q25, which is well above peer levels, attributed to better cost efficiency and the ramp of 800G products [2][6]. Estimate Revisions - Revenue estimates for 2025-2027 have been revised upward by up to 10%, and net profit estimates have been increased by up to 40% due to the reversal of negative pricing impacts from tariffs and stronger-than-expected margin performance [8][9]. - The new revenue estimates for 2025E are Rmb17.12 billion, with a gross margin projected at 48.8% [10][17]. Market Position and Valuation - Eoptolink is trading near its historical trough level P/E, which is considered attractive given the expected growth and profitability [15]. - The report highlights that the stock's valuation is set in line with the company's trough level P/E during 2021-2025, reflecting uncertainties in the tariff and demand outlook [9][15].